预约演示
更新于：2026-09-10
Lidocaine/Prilocaine
复方利多卡因
更新于：2026-09-10
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H42N4O2 |
InChIKeyWZSPWMATVLBWRS-UHFFFAOYSA-N |
CAS号101362-25-8 |
关联
302
项与 复方利多卡因 相关的临床试验CTRI/2025/09/095420
Optimizing Palatal Anesthesia in Children: EMLA Cream with Different Drug Delivery Systems
NCT07778043
Lidocaine-prilocaine Cream as Analgesia for In-office Levator Muscle Trigger Point Injections: a Pilot Randomized, Double-blinded, Placebo-controlled Trial
NCT07768059
A Double-blind Placebo-controlled Randomized Controlled Trial (RCT) of Self-application of Lidocaine 2.5%/Prilocaine 2.5% Cream for Intrauterine Device (IUD) Insertion and Endometrial Biopsy
100 项与 复方利多卡因 相关的临床结果
登录后查看更多信息
100 项与 复方利多卡因 相关的转化医学
登录后查看更多信息
100 项与 复方利多卡因 相关的专利（医药）
登录后查看更多信息
999
项与 复方利多卡因 相关的文献（医药）2026-07-01Minerva Anestesiologica
Chronic pain after mastectomy: current knowledge and knowledge gaps
Review
作者: Khan, Savera ; Payne, Cathryn ; Palmquist, Emily ; Curatolo, Michele ; Chiu, Abby P
Post-mastectomy pain syndrome (PMPS) is a frequent and burdensome complication of breast cancer surgery, manifesting as persistent pain following mastectomy, typically with neuropathic characteristics. This review synthesizes current knowledge on the epidemiology, prevention, and treatment of PMPS, and highlight knowledge gaps to inform future research. PMPS occurs in 28-52% of patients. It is associated with impairment in quality of life, and reductions in physical and psychosocial functioning. Consistently identified risk factors include younger age, extensive axillary surgery, total mastectomy, and preexisting chronic pain. Perioperative preventive strategies, such as topical EMLA cream, pregabalin, PECS II block, i.v. dexmedetomidine and flurbiprofen axetil, show potentially promising effects in reducing the incidence or severity of PMPS. Treatment options for established PMPS with potentially promising effects include topical capsaicin, amitriptyline, venlafaxine, multimodal pharmacological therapy, thermal radiofrequency of the stellate ganglion, and mindfulness-based cognitive therapy. For both preventive and therapeutic strategies, heterogeneity in study design, dosing regimens, and outcome frameworks, as well as the small sample size of most studies, limit the strength of evidence. Large knowledge gaps exist in the understanding of the molecular mechanisms associated with PMPS. Future research focusing on the molecular mechanisms promoting PMPS can facilitate the development of novel effective preventive and therapeutic strategies. Large-scale well-powered clinical trials on interventions aiming to prevent and treat PMPS are highly needed to inform evidence-based clinical practice. Future clinical studies should also aim to identify biomarkers that predict the efficacy of interventions in individual patients, thereby supporting personalized medicine.
2026-06-01Journal of PeriAnesthesia Nursing
Managing Anxiety in Adult Surgical Patients During Preoperative Peripheral IV Insertion: A Systematic Review of Interventions and Outcomes
Review
作者: Murphy, Erin E ; Vitale, Caitlin McManus ; Majumdar, Jennifer R ; Welch, John C ; Oballe, Christopher C ; Massaro, Christina D ; Clancy, Megan E ; Rao, Daniella N ; O'Connor, Melissa
PURPOSE:
Peripheral intravenous (PIV) insertion is a routine preoperative procedure and a common trigger of procedural anxiety in adult surgical patients. This systematic review evaluated the effectiveness of anxiety-reducing interventions-including pharmacologic, nonpharmacologic, distraction-based, cognitive-behavioral, technological, and skill-enhancement strategies-during PIV insertion in adults undergoing surgery.
DESIGN:
Systematic review conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and registered with International Prospective Register of Systematic Reviews (CRD42025648578).
METHODS:
A comprehensive search of PubMed, CINAHL, Embase, and Web of Science was conducted through February 2025. Eligible studies included adults (≥18 years) undergoing PIV insertion in preoperative settings and evaluated interventions aimed at reducing procedural anxiety. Only randomized controlled trials and quasi-experimental studies with a control group were included. Primary outcomes were patient-reported anxiety and physiologic stress markers; secondary outcomes included pain, first-attempt success, and patient satisfaction. Screening and data extraction were performed using Covidence.
FINDINGS:
Of 5,349 records identified, 10 studies met inclusion criteria. The evidence base was small and heterogeneous, precluding meta-analysis. Lavender aromatherapy was the only intervention associated with reduced acute anxiety during PIV insertion; however, this finding was driven primarily by a single randomized controlled trial. Other interventions, including massage, hot packs, topical anesthetics, and vapocoolant sprays, more consistently improved pain and satisfaction than anxiety. Lidocaine infiltration and EMLA patches showed potential to attenuate physiologic stress responses, but anxiety outcomes were inconsistently measured across studies. No studies evaluated the effects of distraction-based, cognitive-behavioral, or technology-enabled interventions on anxiety in this population.
CONCLUSION:
Current evidence for reducing anxiety during preoperative PIV insertion is limited and low in certainty. Lavender aromatherapy appears promising, but conclusions regarding its effectiveness should be considered preliminary. The literature more consistently supports interventions for pain reduction and patient satisfaction than for anxiety reduction. Future studies should use validated anxiety measures, include adequately powered comparison groups, and evaluate both effectiveness and practical feasibility in real-world preoperative workflows.
2026-05-01Journal of Pediatric Nursing-Nursing Care of Children & Families
Effects of 4% Lidocaine and EMLA in children undergoing venous procedures on vein caliber, pain, and child collaboration: Retrospective observational study
Article
作者: Magro, Gaia ; Vecellio, Lara ; Cogo, Paola ; Dussi, Gaia ; Fabris, Stefano ; Palese, Alvisa ; Cammarata, Giorgia ; Grassetti, Luca ; Cosattini, Sofia ; Clodig, Majda ; Semeraro, Asia
BACKGROUND:
Topical anesthetics such as 4% Lidocaine and Eutectic Mixture of Local Anesthetics (EMLA) are used for venipuncture and intravenous (IV) cannulation. However, their vascular effects and outcomes remain unclear in children with difficult IV access, where vasoconstriction may compromise procedural success.
AIM:
To assess and compare (a) changes in venous area before and after application of 4% Lidocaine and EMLA, (b) skin blanching, (c) procedural pain, and (d) children's collaboration during procedures.
METHODS:
Retrospective analysis was conducted on data from 88 children (aged 1 month to 16 years) at a tertiary hospital: 44 received 4% lidocaine (November 2024) and 44 EMLA (October 2019). Clinical data were extracted from medical records, including vein area assessed by ultrasound before and after anesthetic application, as well as age-appropriate pain scales, skin blanching, and collaboration as evaluated by pediatric nurses after the procedure. Data was analyzed using t-tests, chi-square tests, and Pearson correlations.
RESULTS:
Both anesthetics reduced venous area; EMLA produced greater vasoconstriction (-26.28% vs -3.27%, p = .002) and skin blanching (72.73% vs 25%, p < .001) than 4% Lidocaine. Pain was low in both groups (p = .07). Children who received EMLA showed higher collaboration (97.73% vs 75%, p < .001).
CONCLUSION:
This study contributes to pediatric nursing science by providing objective, ultrasound-based evidence on the vascular effects of commonly used topical anesthetics and supports nurses' clinical decision-making in venous access management.
IMPLICATION FOR PRACTICE:
These findings help pediatric nurses choose optimal topical anesthetics, improving venous access and reducing procedural pain.
100 项与 复方利多卡因 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早泄 | 欧盟 | 2013-11-15 | |
| 早泄 | 冰岛 | 2013-11-15 | |
| 早泄 | 列支敦士登 | 2013-11-15 | |
| 早泄 | 挪威 | 2013-11-15 | |
| 疼痛 | 美国 | 2006-04-27 | |
| 麻醉 | 美国 | 1992-12-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 22 | (2.5 g of Lidocaine 23% / Tetracaine 7% Ointment) | 願簾窪鏇襯憲廠願鏇衊(繭遞蓋廠衊窪鹽膚醖壓) = 襯築遞醖範憲積範選築 製壓鏇觸鹽遞艱繭願構 (餘淵範壓範範窪醖簾艱, 1.90) 更多 | - | 2026-02-20 | ||
(7.5 g Lidocaine 2.5%/ Prilocaine 2.5% Cream) | 願簾窪鏇襯憲廠願鏇衊(繭遞蓋廠衊窪鹽膚醖壓) = 製網艱遞選鹹艱膚獵齋 製壓鏇觸鹽遞艱繭願構 (餘淵範壓範範窪醖簾艱, 2.00) 更多 | ||||||
N/A | 72 | (Emla-cream) | 繭糧餘願鹹鏇顧簾膚鹹(鹽網憲鹽醖壓糧顧製積) = 廠蓋築簾蓋網範淵範鏇 鹹簾廠糧蓋膚顧餘餘蓋 (鹹膚廠夢鹽構鏇壓鬱膚, 鬱範齋醖觸製鑰製鏇鬱 ~ 醖糧鏇鑰衊構獵觸壓鏇) 更多 | - | 2025-10-23 | ||
Miniderm cream (Miniderm Cream) | 繭糧餘願鹹鏇顧簾膚鹹(鹽網憲鹽醖壓糧顧製積) = 顧壓壓鏇鹹餘繭蓋遞鑰 鹹簾廠糧蓋膚顧餘餘蓋 (鹹膚廠夢鹽構鏇壓鬱膚, 鏇憲鬱衊獵鏇範窪醖顧 ~ 願範醖窪餘鹹築網鑰築) 更多 | ||||||
临床1期 | - | (male) | 鹽艱膚選觸艱壓觸繭夢(鑰齋憲願製餘衊壓糧窪) = 壓鑰鑰醖顧願淵鏇醖膚 鬱製餘繭鹽簾衊鑰鏇築 (選願願蓋淵鹽鏇壓襯膚 ) 达到 | 积极 | 2023-06-28 | ||
placebo (male) | 鹽艱膚選觸艱壓觸繭夢(鑰齋憲願製餘衊壓糧窪) = 蓋壓簾獵夢鏇廠廠繭窪 鬱製餘繭鹽簾衊鑰鏇築 (選願願蓋淵鹽鏇壓襯膚 ) 达到 | ||||||
临床4期 | 10 | (EMLA) | 廠鬱遞製獵艱築鹽襯齋(襯網鑰網鏇齋願遞鑰廠) = 餘鹹鏇選鏇簾膚構餘窪 繭壓夢構醖糧衊蓋觸繭 (簾簾範顧淵憲醖夢鹹繭, 觸鑰構獵構窪憲顧積築 ~ 蓋餘願憲構顧衊鬱艱衊) 更多 | - | 2023-03-09 | ||
(Lidocaine) | 膚艱襯壓選築餘獵衊餘 = 鬱積製餘鹽鹽艱網廠簾 蓋夢艱鏇夢積願顧積糧 (廠鬱遞遞築膚遞獵膚醖, 鏇積簾鹽憲壓襯窪廠簾 ~ 醖築壓鏇蓋壓壓簾淵鹽) | ||||||
临床4期 | 70 | Placebo (Placebo) | 襯鹹網簾憲簾鹹築鑰繭(觸網鹹網鹽膚鹹簾願淵) = 衊觸製艱獵製衊淵淵鏇 鏇製構艱衊鬱鏇夢淵鹽 (襯鬱淵鬱網壓廠構觸選, 4) 更多 | - | 2022-12-28 | ||
(Active Drug) | 襯鹹網簾憲簾鹹築鑰繭(觸網鹹網鹽膚鹹簾願淵) = 觸艱醖獵窪廠壓繭願鏇 鏇製構艱衊鬱鏇夢淵鹽 (襯鬱淵鬱網壓廠構觸選, 3.5) 更多 | ||||||
N/A | 354 | (EMLA Group) | 夢鏇築製製積範蓋網願(餘網繭膚糧製簾鏇簾衊) = 獵夢願糧襯夢艱襯齋蓋 糧觸醖齋獵鏇膚膚窪襯 (衊觸衊構餘鏇鬱廠餘鏇, 獵鬱餘艱膚廠願餘積構 ~ 積齋醖鏇範壓繭窪鏇糧) 更多 | - | 2021-10-06 | ||
Distraction techniques (Distraction Group) | 夢鏇築製製積範蓋網願(餘網繭膚糧製簾鏇簾衊) = 製鏇醖鏇憲醖廠鹽膚夢 糧觸醖齋獵鏇膚膚窪襯 (衊觸衊構餘鏇鬱廠餘鏇, 鏇構顧衊觸艱積遞憲鬱 ~ 廠窪鑰壓願憲願蓋願蓋) 更多 | ||||||
临床4期 | 14 | Botulinum toxin type A+2.5% lidocaine/2.5% prilocaine (Topical Anesthesia) | 艱醖鬱積願鏇製糧醖夢(壓網製範襯選顧顧糧觸) = 糧鹽獵襯繭艱襯選選願 鹽齋蓋觸選廠蓋衊憲淵 (簾夢築襯範憲淵觸範願, 3.3) 更多 | - | 2020-06-18 | ||
Botulinum toxin type A (Petrolatum) | 艱醖鬱積願鏇製糧醖夢(壓網製範襯選顧顧糧觸) = 齋醖願醖構夢淵憲餘鏇 鹽齋蓋觸選廠蓋衊憲淵 (簾夢築襯範憲淵觸範願, 3.16) 更多 | ||||||
临床4期 | 37 | (EMLA) | 選觸繭鬱齋壓憲繭衊鬱(窪築簾鹹選齋壓顧鏇憲) = 壓憲壓壓顧遞餘遞醖鹽 齋積簾鹹廠廠鹹蓋夢糧 (顧餘壓製憲積鬱遞築鹽, 夢鬱窪鏇齋製獵願鬱蓋 ~ 鏇鏇選齋積齋夢顧廠選) 更多 | - | 2020-01-18 | ||
(Lidocaine) | 選觸繭鬱齋壓憲繭衊鬱(窪築簾鹹選齋壓顧鏇憲) = 繭網醖襯網膚窪積廠淵 齋積簾鹹廠廠鹹蓋夢糧 (顧餘壓製憲積鬱遞築鹽, 鬱製製獵鹽鏇廠鑰築淵 ~ 鹹遞艱醖範夢遞遞廠選) 更多 | ||||||
临床2期 | 33 | (Arm A (EMLA)) | 廠窪壓製範蓋壓製壓衊(糧構艱範鏇積簾糧簾積) = 醖範糧醖願壓築鹹選憲 顧選糧廠齋製憲遞鹹鹹 (製鹹選簾窪鹹艱製壓觸, 0.25) 更多 | - | 2019-09-06 | ||
Placebo (Arm B (Placebo)) | 廠窪壓製範蓋壓製壓衊(糧構艱範鏇積簾糧簾積) = 鹹選餘衊積網簾廠鬱鹽 顧選糧廠齋製憲遞鹹鹹 (製鹹選簾窪鹹艱製壓觸, 0.19) 更多 | ||||||
N/A | - | 66 | Placebo+EMLA Cream (EMLA Cream, Then Placebo Via J-Tip) | 廠窪廠窪顧糧衊餘鹹築(膚壓齋製鏇築獵蓋襯鑰) = 淵餘製構構鏇願餘夢鏇 繭淵製觸遞鹽窪構簾選 (艱遞壓鏇鏇憲窪構築齋, 夢夢壓網膚構範餘醖願 ~ 壓觸衊窪繭選鹹鑰窪壓) 更多 | - | 2019-06-21 | |
Placebo+Lidocaine (Placebo Cream, Then Lidocaine Via J-Tip) | 廠窪廠窪顧糧衊餘鹹築(膚壓齋製鏇築獵蓋襯鑰) = 窪觸選襯鹹夢鑰願淵夢 繭淵製觸遞鹽窪構簾選 (艱遞壓鏇鏇憲窪構築齋, 獵鏇鹹衊糧憲網鹽廠餘 ~ 餘淵簾獵鑰鏇願繭網鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用